GlaxoSmithKline Pharmaceuticals received a tax demand of Rs 23.21 crore from CPC for Assessment Year 2023-24.
The demand arose post scrutiny assessment; the company is filing an appeal before the appellate authority.
No financial statement impact is reported currently; disclosure made under SEBI LODR Regulation 30.